Evidence map›Paper›PMID 41698419›Full record

ArticleEuropean journal of dentistry2026

Dental Pulp Stem Cell-Derived Secretome-Induced Reprogramming of Tongue Tumor Microenvironment.

Ferry Sandra, Dewi Ranggaini, Johni Halim, Natalia Tjingson, Melanie Sadono Djamil, Janti Sudiono, Muhammad Ihsan Rizal, Nurrani Mustika Dewi, Alifah Evi Scania, Kyung Hoon Lee

Abstract read
In one paragraph

Article in European journal of dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ferry SandraDepartment of Biochemistry and Molecular Biology, Division of Oral Biology, Faculty of Dentistry, Universitas Trisakti, Indonesia.ORCID 0000-0002-5852-1074
Dewi RanggainiDepartment of Physiology, Division of Oral Biology, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia.
Johni HalimDepartment of Physiology, Division of Oral Biology, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia.
Natalia TjingsonMaster of Dental Science Program, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia.
Melanie Sadono DjamilDepartment of Biochemistry and Molecular Biology, Division of Oral Biology, Faculty of Dentistry, Universitas Trisakti, Indonesia.
Janti SudionoDepartment of Oral and Maxillofacial Pathology, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia.
Muhammad Ihsan RizalDepartment of Biochemistry and Molecular Biology, Division of Oral Biology, Faculty of Dentistry, Universitas Trisakti, Indonesia.ORCID 0000-0002-2370-038X
Nurrani Mustika DewiThe Prodia Education and Research Institute, Jakarta, Indonesia.
Alifah Evi ScaniaThe Prodia Education and Research Institute, Jakarta, Indonesia.
Kyung Hoon LeeResearch Institute, Ballys Co. Ltd, Incheon, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract: Oral tongue cancer is among the most aggressive malignancies in the head and neck region, driven by a complex tumor microenvironment (TME) that fosters tumor progression, immune evasion, and therapy resistance. Conventional treatments often fail to address the stromal and immunological intricacies of the TME, highlighting the need for microenvironment-targeted therapies. One promising strategy involves the use of dental pulp stem cell-derived secretome (DPSC-Sec), which contains a broad range of bioactive molecules, cytokines, chemokines, growth factors, and extracellular vesicles enriched with regulatory microRNAs. This review explores the potential of DPSC-Sec as a reprogramming agent for modulating the TME in tongue cancer. Evidence suggests that DPSC-Sec may inhibit cancer-associated fibroblast activation, reprogram immunosuppressive cells, remodel the extracellular matrix, normalize aberrant angiogenesis, and regulate oncogenic signaling pathways. The therapeutic quality of DPSC-Sec is significantly influenced by priming methods, which can enhance its potency. While preclinical data are promising, clinical translation requires validation in orthotopic and immunocompetent models, GMP-compliant production, and thorough safety evaluation, especially regarding tumorigenicity and angiogenic effects. Integration with biomaterials, nanocarriers, or conventional therapies may further boost efficacy. This review consolidates current findings on DPSC-Sec and its mechanisms in TME modulation, underscoring its translational potential and future directions for developing targeted therapies in tongue cancer.

Identifiers

PMID41698419
PMCPMC13623487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.